LYEL
Price
$35.09
Change
-$3.51 (-9.09%)
Updated
Dec 26 closing price
Capitalization
745.45M
Intraday BUY SELL Signals
RLYB
Price
$0.69
Change
-$0.04 (-5.48%)
Updated
Dec 26 closing price
Capitalization
29.05M
79 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LYEL vs RLYB

Header iconLYEL vs RLYB Comparison
Open Charts LYEL vs RLYBBanner chart's image
Lyell Immunopharma
Price$35.09
Change-$3.51 (-9.09%)
Volume$127.52K
Capitalization745.45M
Rallybio
Price$0.69
Change-$0.04 (-5.48%)
Volume$338.58K
Capitalization29.05M
LYEL vs RLYB Comparison Chart in %
LYEL
Daily Signal:
Gain/Loss:
RLYB
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
LYEL vs. RLYB commentary
Dec 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LYEL is a Hold and RLYB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 28, 2025
Stock price -- (LYEL: $35.09 vs. RLYB: $0.69)
Brand notoriety: LYEL and RLYB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LYEL: 201% vs. RLYB: 147%
Market capitalization -- LYEL: $745.45M vs. RLYB: $29.05M
LYEL [@Biotechnology] is valued at $745.45M. RLYB’s [@Biotechnology] market capitalization is $29.05M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LYEL’s FA Score shows that 0 FA rating(s) are green whileRLYB’s FA Score has 1 green FA rating(s).

  • LYEL’s FA Score: 0 green, 5 red.
  • RLYB’s FA Score: 1 green, 4 red.
According to our system of comparison, RLYB is a better buy in the long-term than LYEL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LYEL’s TA Score shows that 4 TA indicator(s) are bullish while RLYB’s TA Score has 2 bullish TA indicator(s).

  • LYEL’s TA Score: 4 bullish, 3 bearish.
  • RLYB’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, LYEL is a better buy in the short-term than RLYB.

Price Growth

LYEL (@Biotechnology) experienced а +5.28% price change this week, while RLYB (@Biotechnology) price change was -12.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.36%. For the same industry, the average monthly price growth was +0.27%, and the average quarterly price growth was +54.56%.

Reported Earning Dates

RLYB is expected to report earnings on Mar 17, 2026.

Industries' Descriptions

@Biotechnology (+0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LYEL($745M) has a higher market cap than RLYB($29M). LYEL YTD gains are higher at: 174.141 vs. RLYB (-28.375). RLYB has higher annual earnings (EBITDA): -38.14M vs. LYEL (-188.82M). LYEL has more cash in the bank: 320M vs. RLYB (59.3M). RLYB has less debt than LYEL: RLYB (198K) vs LYEL (44.3M). RLYB has higher revenues than LYEL: RLYB (674K) vs LYEL (41K).
LYELRLYBLYEL / RLYB
Capitalization745M29M2,569%
EBITDA-188.82M-38.14M495%
Gain YTD174.141-28.375-614%
P/E RatioN/AN/A-
Revenue41K674K6%
Total Cash320M59.3M540%
Total Debt44.3M198K22,374%
TECHNICAL ANALYSIS
Technical Analysis
LYELRLYB
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 4 days ago
86%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 6 days ago
84%
Bullish Trend 9 days ago
88%
Declines
ODDS (%)
N/A
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
LYEL
Daily Signal:
Gain/Loss:
RLYB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WASYX22.940.05
+0.22%
Nomura Asset Strategy Fund Cl Y
BAFWX46.710.09
+0.19%
Brown Advisory Sustainable Growth I
NUGIX34.810.04
+0.12%
Nuveen Global Dividend Growth I
GGGAX66.640.03
+0.05%
Gabelli Global Growth A
FICGX14.15N/A
N/A
Cantor Fitzgerald Large Cap Fcs Cl A

LYEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, LYEL has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LYEL jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYEL
1D Price
Change %
LYEL100%
-9.09%
VCYT - LYEL
46%
Loosely correlated
-0.65%
RLYB - LYEL
40%
Loosely correlated
-6.01%
BEAM - LYEL
37%
Loosely correlated
-0.57%
CRBU - LYEL
36%
Loosely correlated
-1.16%
RXRX - LYEL
36%
Loosely correlated
-3.41%
More

RLYB and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLYB has been loosely correlated with PROK. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if RLYB jumps, then PROK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLYB
1D Price
Change %
RLYB100%
-6.01%
PROK - RLYB
45%
Loosely correlated
-1.56%
PXXLF - RLYB
44%
Loosely correlated
N/A
LYEL - RLYB
40%
Loosely correlated
-9.09%
RGNX - RLYB
39%
Loosely correlated
-2.07%
ATXS - RLYB
39%
Loosely correlated
-0.23%
More